MRNA

Pharma

Moderna

197.28

▼ 1.60 (-0.80%)

Needs attentionPrice 89% above estimated priceEstimate shown is the peer P/S-implied price, not the DCF: the discounted-cash-flow model is not meaningful for this name (negative enterprise value). Value it on relative multiples and Level-3 assumptions, not the raw DCF.Revenue is dominated by the COVID vaccine franchise, well past the 40% single-product threshold, and that concentrated base is under a credible competitive and demand threat: Q2 2026 product sales fell 18% YoY and the franchise is in a seasonal trough. Diversification hinges on mNEXSPIKE's European ramp and the mRNA-1010 August 2026 PDUFA; until those scale, concentration risk is the dominant vulnerability.

Price · volume · estimated price

Chart

197.28

Sep 28, 2026 · Vol 12.8M

Thesis

At a glance

No thesis note yet.

Analyst view · model-derived

The call

Speculative Sell · UnderweightMedium conviction

12-mo target

$21.92

-89% vs price

Bull case

—

Bear case

—

Accumulate below

$17.54

ThesisWe see limited upside: at $197.28 the shares sit 89% above our $21.92 intrinsic estimate.

ValuationThe DCF is not meaningful here — its terminal year is still cash-flow-negative — so we anchor on the peer EV/EBITDA multiple at $21.92 rather than the raw intrinsic number.

What's priced inAt $197.28, the tape is discounting growth beyond the 100% our model will extrapolate — i.e. pricing an outcome we treat as unsupported.

LevelsHistory is too thin for a scenario band, so we frame value on the $21.92 point estimate and would look to accumulate below $17.54 (~25% margin of safety).

Risks to ratingThe principal risk is assumption sensitivity around the growth and margin path; no distress rule is firing.

Bottom lineBottom line: sell into strength; downside to our $21.92 estimate. Medium-conviction call.

Model-derived synthesis of the computed valuation — not investment advice.

Market signals · technical

Price & volume signals

Technical signals from price history, for your own read of market timing. These never affect the Estimated Price — they sit apart from the valuation by design.

Trend

Above averages

price vs SMAs

RSI (14)

overbought

Volume trend

rising

+14% (10 vs 10)

SMA 20

158.66

SMA 50

112.82

SMA 200

n/a

Forecast recalibration · draftedneeds your review

Drafted from official evidence. It does not change the Estimated Price until you approve it.

10-year curve · deepseek-v4-flash

Official H1/Q1 2026 filings show revenue is inflecting: H1 total revenue doubled to $534M on the mNEXSPIKE European ramp and management guides to a return to sales growth in 2026, but Q2 product sales fell 18% YoY and the COVID franchise remains pressured. Costs remain heavily distorted by the Arbutus/Genevant settlements (~$950M Q3 payment, $878M Q1 charge, potential $1.3B), $79M inventory write-downs, and heavy R&D, producing a $2.1B H1 net loss; near-term EBITDA margins stay deeply negative. Cost discipline and a modest R&D reduction support a gradual long-term path toward the 30% category margin, but the recovery is not evidenced until later years. Where evidence is silent (after 2026), we revert to the current curve. Auto-corrections: EBITDA margin Y1: -1.5 out of [-1, 0.6] — clamped to -1.

	Y1 FY2026	Y2 FY2027	Y3 FY2028	Y4 FY2029	Y5 FY2030	Y6 FY2031	Y7 FY2032	Y8 FY2033	Y9 FY2034	Y10 FY2035
Revenue growth	5.00% was 5.00%	0.28% was 0.28%	0.56% was 0.56%	0.83% was 0.83%	1.11% was 1.11%	1.39% was 1.39%	1.67% was 1.67%	1.94% was 1.94%	2.22% was 2.22%	2.50% was 2.50%
EBITDA margin	-100.00% was -100.00%	-100.00% was -100.00%	-100.00% was -100.00%	-88.18% was -88.18%	-68.49% was -68.49%	-48.79% was -48.79%	-29.09% was -29.09%	-9.39% was -9.39%	10.30% was 10.30%	30.00% was 30.00%

Evidence cited

filing 10-Q — Moderna's H1 2026 results show a company in transitio…filing 8-K — This 8-K is a routine form filing that merely announce…filing 10-Q — Moderna's Q1 2026 results reflect strong revenue grow…

Estimated Price3-level modelrecomputed live

21.92-88.89% vs 197.28

Beta 1.19: Drugs (Biotechnology) unlevered 1.18 (Damodaran, Global, Jan 2026) relevered at this company's own market D/E 0.8%.

Estimate shown is the peer P/S-implied price, not the DCF: the discounted-cash-flow model is not meaningful for this name (negative enterprise value). Value it on relative multiples and Level-3 assumptions, not the raw DCF.

usedPeer P/S — drives the estimate

DCF invalid → mechanical peer multiple

21.92

offDCF core (L1)

-6.48

offPeer-haircut path (L2)

-6.48

The DCF path is discarded— its final-year cash flow is negative, so it isn't meaningful. The two struck figures are shown for transparency only; they do not feed the 21.92 estimate.

WACC build-up

Cost of equity (CAPM)9.22%

After-tax cost of debt4.90%

Equity / debt weight99.25% / 0.75%

WACC9.19%

Level 2 · cross-check

Peer-implied (P/S)21.92

DCF vs peer-129.57%

No reliability rule firing — Level 1 passes through.

Leverage & debt serviceability

Total debt$591.0M

Net debt−$1.13B

Debt / revenue30.40%

Interest expense—

Interest expense not ingested — coverage not computed.

Serviceability lens (EBIT ÷ interest) — separate from the WACC and the leverage haircut; never moves the Estimated Price.

Valuation methods · side by side

DCF (intrinsic)low

-6.48

Not meaningful — negative enterprise value; a single-scenario DCF has broken down here.

Peer P/Smedium

21.92

Shown side by side, never averaged. Headline uses the DCF, with the peer multiple as fallback when the DCF is invalid.

· Interest expense not ingested — cost of debt proxied as risk-free + 2%.
· DCF not meaningful (negative enterprise value) — headline falls back to the peer P/S-implied price.

Synthesis · cross-lens readlow confidencemixed

The estimate sits -89% below the market, though the lenses conflict or the data is thin — a low-confidence read, lean on your own judgement.

A reading of the numbers already computed — not a new estimate. It never overrides a method, rule, or approval gate.

DCF (intrinsic)n/a

Not meaningful — the DCF's final year is still cash-flow-negative, so it can't anchor value here.

Peer EV/EBITDArich vs price

Peer-implied $21.92 — -89% vs price; DCF sits -130% vs peer.

Scenario bandn/a

DCF not meaningful — a scenario band on a broken DCF would mislead.

Debt serviceabilityn/a

Interest coverage not computable — no interest figure ingested.

Distress / reliabilityneutral

No reliability rule firing — the Level-1 DCF passes through un-haircut.

Technicals (timing)timing

Price above its moving averages, RSI overbought. Timing only — never part of the value read.

Why this read

·DCF is not meaningful (negative terminal-year cash flow); the headline leans on the peer multiple instead.
·Peer multiple implies $21.92 (-89% vs price) — reads rich.
·Only one value lens is available — the read rests on a single method, uncorroborated.
·No scenario band — history is too thin to gauge how assumption-sensitive the estimate is.

Trailing twelve months · from XBRL

Fundamentals

as of Jun 30, 2026

Revenue

$1.94B

Gross margin

55.35%

EBITDA

−$2.86B

EBITDA margin

-147.27%

Net income

−$2.82B

EPS

-7.07

Cash

$1.72B

Total debt

$591.0M

Net debt

−$1.13B

Net leverage

—

Book value

$6.76B

Backlog

—

Position

No open position. Record a trade on the Portfolio tab and it flows into this card.

Company status · synthesized

Status

Full history →Sep 28, 2026

What happened

—

Where it stands

Moderna is a revenue-generating commercial-stage pharma name, not a pre-revenue story, so the runway rule is not in play, and there is no order-book or customer-capex exposure of the type the RadTech/MedTech rules target. On the balance sheet, the company is not leveraged in the mechanical sense: total debt of $591M against $1.723B of cash (filings cite roughly $6.9B of cash and investments) leaves it in a net-cash position, so the net-leverage rule does not fire, and because net leverage is not high, the distressed-multiple rule does not trigger either.

Filings & extraction

8-KSep 01, 2026Item 1.01,2.03,3.02,8.01,9.01
Source ↗
Moderna raised $3.0 billion of zero-coupon convertible senior notes due 2032, with net proceeds of approximately $2.96 billion after $328.8 million spent on capped calls. The initial conversion price of ~$210.58 represents a 47.5% premium to the $142.77 reference stock price, and the capped calls cap effective dilution offset at ~$392.62 per share. Proceeds are earmarked for general corporate purposes, with stated potential uses including oncology growth investment and debt repayment; the filing provides no operational guidance, backlog, or capex plans. Investors should weigh the balance-sheet flexibility from this low-cost financing against potential conversion dilution of up to roughly 21 million shares, and note the Notes' unsecured status, fundamental-change repurchase feature, and redemption provisions.
Show extraction ▾Hide extraction ▴
MD&A highlights
·Completed private offering of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032, including full exercise of initial purchasers' option to purchase an additional $400,000,000.
·Net proceeds from the offering were approximately $2,957.3 million after deducting initial purchasers' discounts and commissions and estimated offering expenses; $328.8 million was used to pay the cost of capped call transactions.
·The initial conversion rate is 4.7487 shares per $1,000 principal (initial conversion price approximately $210.58 per share), a premium of approximately 47.5% over the last reported sale price of $142.77 on August 27, 2026.
·Capped call transactions were entered into with a cap price initially equal to approximately $392.62 per share, representing a premium of 175.0% over the $142.77 reference stock price.
Debt / leverage
The Company issued $3.0 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032 as general senior unsecured obligations; the Notes bear no regular interest and principal does not accrete, with special interest only in specified circumstances. The Notes mature March 1, 2032, are initially convertible at 4.7487 shares per $1,000 principal (initial conversion price ~$210.58, a 47.5% premium to the $142.77 close), and may be redeemed for cash on or after September 6, 2029 if the stock price has been at least 130% of the conversion price for 20 of 30 trading days, subject to a partial redemption limitation requiring at least $100 million of Notes to remain outstanding; a cleanup redemption is permitted if less than $100 million remains outstanding. Holders may require repurchase at 100% of principal plus accrued special interest upon a fundamental change. The Company also entered into capped call transactions covering the underlying shares with a cap price of approximately $392.62 per share.
Key risks
·Conversion of the Notes could cause dilution; based on the initial conversion rate the Notes are convertible into 14,246,100 shares and, in limited circumstances, a maximum of 21,012,600 shares.
·The capped call transactions only partially reduce dilution or offset cash payments, as the offset is subject to a cap price of approximately $392.62 per share.
·The Notes are unsecured, and events of default include bankruptcy/insolvency events and cross-default on other indebtedness above $250 million, which could accelerate repayment obligations.
·The forward-looking statements in the filing involve known and unknown risks, uncertainties, and other factors, including those described in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and subsequent SEC filings.
Forward-looking · richest in 10-Ks
Strategic priorities
·Potential use of proceeds: flexibility to invest in the growth of its oncology business.
·Potential use of proceeds: repayment of debt.
Capital allocation
The Company's net proceeds from the offering were approximately $2,957.3 million after deducting initial purchasers' discounts and commissions and estimated offering expenses. The Company used $328.8 million of the net proceeds to pay the cost of the capped call transactions and expects to use the remaining net proceeds for general corporate purposes, which may include the flexibility to invest in the growth of its oncology business and repayment of debt.
Extracted by deepseek-v4-flash · Sep 01, 2026
8-KJul 31, 2026Item 2.02,9.01
Source ↗
This 8-K is a routine form filing that merely announces the issuance of a press release (Exhibit 99.1) reporting Moderna's Q2 2026 financial results. The body of the 8-K contains no substantive MD&A, guidance, risk factors, or capital allocation discussion; all qualitative content would reside in the attached press release, which was not provided in the text. Accordingly, no financial or strategic insights can be extracted from the document itself.
Show extraction ▾Hide extraction ▴
Extracted by deepseek-v4-flash · Aug 01, 2026
10-QJul 31, 2026
Source ↗
Moderna's H1 2026 results show a company in transition: total revenue doubled to $534 million on mNEXSPIKE's European ramp, but the $2.1 billion net loss and a 401% jump in cost of sales reflect the $950 million Arbutus/Genevant settlement, $79 million of inventory write-downs, and continued heavy R&D spending. Q2 product sales fell 18% year-over-year to $94 million, underscoring the seasonal trough and COVID franchise pressure. Liquidity remains adequate with roughly $6.9 billion in cash and investments, though the Q3 2026 $950 million settlement payment and the $1.5 billion Ares facility (with $600 million drawn) add balance-sheet obligations; the $500 million minimum cash covenant appears comfortably covered. Key catalysts are mRNA-1010's August 5, 2026 PDUFA date and potential Phase 3 adjuvant melanoma data in 2026, while the norovirus Phase 3 miss and patent litigation (including possible $1.3 billion appeal exposure) are important downside risks. The company retains $1.7 billion of buyback authority but has not repurchased shares.
Show extraction ▾Hide extraction ▴
MD&A highlights
·Q2 2026 total revenue was $145 million versus $142 million in Q2 2025; net loss per share improved to $(1.97) from $(2.13).
·H1 2026 total revenue increased 114% to $534 million from $250 million, driven primarily by higher COVID product sales including mNEXSPIKE; net loss widened to $2,125 million from $1,796 million.
·In April 2026, the European Commission granted marketing authorization for mCOMBRIAX (mRNA-1083), Moderna's fourth approved product, for flu+COVID prevention in adults 50 and older.
·In June 2026, FDA's VRBPAC unanimously voted that mRNA-1010's benefits outweigh risks for influenza prevention in adults 50-64 and 65+; PDUFA date is August 5, 2026.
·In June 2026, Moderna expanded its CEPI collaboration with up to $50 million committed to develop a Bundibugyo ebolavirus vaccine candidate.
·The Phase 3 interim analysis of norovirus vaccine mRNA-1403 did not meet statistical criteria for early success; the trial is ongoing and remains blinded while enrolling an additional cohort.
Debt / leverage
In November 2025, Moderna entered a $1.5 billion senior secured term loan facility (Ares Capital as administrative agent): a $600 million initial term loan was funded at closing, and $900 million of delayed draw commitments remain ($400 million available through November 2027 and $500 million through November 2028, subject to regulatory milestones). Borrowings bear interest at Term SOFR plus 5.50% or base rate plus 4.50%; the initial term loan's interest rate was approximately 9.20% at June 30, 2026. The facility matures November 24, 2030 and requires minimum cash and liquid securities of $500 million (rising to $750 million if more than $1.0 billion is drawn), not tested when the trailing 30-day average market cap exceeds $5.0 billion. No delayed draw amounts were outstanding; the carrying amount of the initial term loan was $591 million.
Key risks
·Norovirus vaccine mRNA-1403 failed to meet early-success criteria at the Phase 3 interim analysis; the trial continues with an additional cohort, creating clinical and commercial uncertainty.
·The Arbutus/Genevant settlement requires a $950 million lump-sum payment in Q3 2026; the related appeal could require an additional payment of up to $1.3 billion, for which no accrual has been recorded.
·Ongoing patent litigation includes actions against Pfizer/BioNTech, GSK, Northwestern, Monsanto, Translate Bio/Sanofi and CureVac, plus shareholder class/derivative suits related to RSV vaccine statements.
·H1 2026 cost of sales included $884 million of Arbutus/Genevant litigation-related royalty expense and $79 million of inventory write-downs, pressuring margins.
·Regulatory approvals are uncertain: mRNA-1010 has an August 5, 2026 PDUFA date, mCOMBRIAX EU launch depends on national procedures, and a U.S. refiling for the flu+COVID combination vaccine awaits FDA guidance.
·Sales are highly seasonal, with COVID and RSV demand concentrated in fall/winter; Q2 2026 net product sales declined 18% year-over-year to $94 million.
Forward-looking · richest in 10-Ks
Outlook / tone
Management states an 'expectation regarding a return to sales growth in 2026' and 'anticipates seasonal fluctuations in demand for our COVID and RSV vaccines, with higher sales expected during the fall and winter seasons.' The filing also cites anticipated milestones including 'Phase 3 adjuvant melanoma data potentially in 2026,' potential data in 2026 for mRNA-3927, and 'potential approvals are expected to begin in 2026' for mRNA-1010, with a PDUFA date of August 5, 2026. These forward-looking statements are based on management's beliefs and assumptions as of the filing date.
Strategic priorities
·Return to sales growth in 2026 by driving use of commercial products.
·Execute on the prioritized research and development portfolio and deliver cost efficiency across the business.
·Expand the respiratory franchise: commercialize mCOMBRIAX across the EU and pursue mRNA-1010 approvals, with potential approvals expected to begin in 2026.
·Advance oncology, including mRNA-4157 (intismeran autogene) with Merck, with Phase 3 adjuvant melanoma data expected potentially in 2026.
·Progress rare disease therapeutics: mRNA-3927 propionic acidemia registrational study has reached target enrollment with potential data in 2026; mRNA-3705 pivotal trial decision deferred.
·Extend partnerships, such as the expanded CEPI collaboration for BDBV and the Recordati collaboration for mRNA-3927.
Capex / expansion
Purchases of property, plant and equipment totaled $99 million in H1 2026, with an additional $36 million of non-cash purchases included in payables and accruals; no formal forward capex plan is disclosed in this Form 10-Q.
Capital allocation
As of June 30, 2026, $1.7 billion of the Board's 2022 Repurchase Programs authorization remained outstanding with no expiration date; no shares were repurchased during the three or six months ended June 30, 2026 or 2025. H1 2026 financing activities provided $31 million, primarily from $42 million of equity plan proceeds offset by tax settlements and financing lease payments.
Extracted by deepseek-v4-flash · Aug 01, 2026
8-KMay 01, 2026Item 2.02,9.01
Source ↗
This 8-K filing by Moderna, Inc. on May 1, 2026, merely furnishes a press release (Exhibit 99.1) announcing first quarter 2026 financial results. The filing itself contains no quantitative or qualitative details beyond the incorporation of that press release. No MD&A highlights, guidance, backlog, debt commentary, key risks, capex plans, strategic priorities, outlook, risk factor changes, or capital allocation information are provided in the 8-K body. Analysts would need to review the attached press release for substantive content.
Show extraction ▾Hide extraction ▴
Extracted by deepseek-v4-flash · Jul 23, 2026
10-QMay 01, 2026
Source ↗
Moderna's Q1 2026 results reflect strong revenue growth from international COVID vaccine deliveries under long-term government partnerships, but the bottom line was heavily impacted by a $878 million litigation settlement charge related to Arbutus/Genevant. Excluding this, operating expenses declined due to disciplined cost management. The company maintains a solid balance sheet with $7.4 billion in equity and $590 million in debt, though a potential $1.3 billion additional payment from the Arbutus appeal remains a key risk. Guidance points to revenue growth in 2026, stable to lower cost of sales (ex-settlement), and continued expense discipline. Strategic priorities center on advancing the pipeline (mCOMBRIAX approval, intismeran data, norovirus), partnerships, and IP resolution, while capital allocation is constrained by debt covenants. The outlook is cautiously positive on top-line expansion but tempered by legal uncertainties and seasonal demand patterns.
Show extraction ▾Hide extraction ▴
MD&A highlights
·Total revenue for Q1 2026 was $389 million, up 260% from $108 million in Q1 2025, driven by a 309% increase in net product sales to $352 million, primarily from international COVID vaccine deliveries under long-term government partnerships.
·Net loss was $(1,343) million, or $(3.40) per share, compared to $(971) million, or $(2.52) per share in the prior year; the increase was largely due to an $878 million litigation settlement charge recorded in cost of sales.
·Cost of sales was $955 million, including $895 million in third-party royalties (of which $878 million related to the Arbutus/Genevant settlement), $38 million in inventory write-downs, and amortization of the associated intangible asset.
·Research and development expenses decreased 24% to $649 million, driven by lower clinical manufacturing costs, reduced consulting, and lower headcount.
·Selling, general and administrative expenses decreased 18% to $173 million, reflecting cost discipline and streamlined operations.
·As of March 31, 2026, the company had three commercial products (Spikevax, mNEXSPIKE, mRESVIA) and received EU marketing authorization for mCOMBRIAX in April 2026.
Guidance
Product sales are expected to return to growth in 2026, supported by the full-year impact of long-term strategic partnerships with government entities. Cost of sales, excluding the Arbutus/Genevant settlement, is anticipated to remain at a relatively consistent level compared to 2025, with continued manufacturing productivity improvements. Research and development expenses are expected to see a modest reduction in 2026 compared to 2025, driven by portfolio prioritization and disciplined cost management. Selling, general and administrative expenses are expected to remain relatively consistent with 2025.
Debt / leverage
As of March 31, 2026, the company had $590 million in long-term debt (net of discount and issuance costs) under a $1.5 billion senior secured credit agreement with Ares Capital, consisting of a $600 million initial term loan (interest rate ~9.17%) and $900 million of undrawn delayed draw commitments. The company was in compliance with all covenants, including a minimum cash requirement of $500 million (or $750 million if more than $1.0 billion is drawn) unless the trailing 30-day market capitalization exceeds $5.0 billion.
Key risks
·Potential additional payment of up to $1.3 billion related to the Arbutus/Genevant settlement appeal, which could materially impact financial condition.
·Ongoing patent litigation with Pfizer/BioNTech, GSK, Northwestern University, and others, which could affect commercial products and pipeline.
·Dependence on seasonal demand for respiratory vaccines, with higher sales expected in fall/winter.
·Execution risks in R&D pipeline, including clinical trial enrollment, regulatory approvals, and commercialization.
·Manufacturing and supply chain risks, including reliance on third-party suppliers and internal capacity.
·Intellectual property challenges and royalty obligations that could impact cost of sales.
·Need for additional financing to support operations and debt service; the credit agreement includes restrictive covenants.
Forward-looking · richest in 10-Ks
Outlook / tone
Product sales are expected to return to growth in 2026, supported by the full-year impact of long-term strategic partnerships with government entities. We anticipate a modest reduction in research and development expenses in 2026 compared to 2025, driven by continued portfolio prioritization, disciplined cost management, and a focused approach to pipeline execution. We expect selling, general and administrative expenses in 2026 to remain at a level relatively consistent with 2025, reflecting an efficient and scalable operating structure.
Strategic priorities
·Advance the mRNA pipeline across infectious disease vaccines, oncology therapeutics, and rare disease therapeutics.
·Execute strategic collaborations, including the Recordati partnership for propionic acidemia (mRNA-3927) and the Mexico government agreement for local manufacturing.
·Deliver cost efficiency through portfolio prioritization, disciplined cost management, and streamlined operations.
·Secure regulatory approvals and commercial launches for key products, including mCOMBRIAX in the EU and mRNA-1010 seasonal flu vaccine.
·Resolve intellectual property disputes, as demonstrated by the Arbutus/Genevant settlement, to provide certainty for the infectious disease portfolio.
·Advance late-stage pipeline programs, including intismeran autogene (individualized neoantigen therapy) with Merck and the norovirus vaccine candidate.
Capital allocation
As of March 31, 2026, $1.7 billion remained available under the 2022 share repurchase program, with no shares repurchased during the quarter. The company did not pay dividends. Capital allocation priorities include funding operations, R&D, and debt service; the credit agreement restricts certain payments including dividends and share repurchases subject to covenants.
Risk-factor changes
No material changes to risk factors from the 2025 Form 10-K, except the new risk associated with the Arbutus/Genevant settlement appeal, which could require an additional payment of up to $1.3 billion depending on the outcome.
Extracted by deepseek-v4-flash · Jul 23, 2026

View all filings (+13) ▾

8-KJul 08, 2026Item 5.02,7.01,9.01routine
Source ↗
Routine 8-K — kept for the record, not extracted.
8-KMay 11, 2026Item 5.03,5.07,9.01routine
Source ↗
Routine 8-K — kept for the record, not extracted.
8-KMar 05, 2026Item 1.01unprocessed
Source ↗
Facts ingested; qualitative extraction pending.
10-KFeb 20, 2026
Source ↗
Moderna's 2025 10-K depicts a company navigating the post-pandemic landscape: revenue of $1.9B (mostly COVID vaccines) with net losses, but management forecasts 2026 growth underpinned by long-term government partnerships and mNEXSPIKE adoption. The pipeline shows promise—intismeran autogene (melanoma) with sustained efficacy data, and several late-stage vaccine candidates (flu, combo, norovirus) approaching potential launches. Operational discipline is a focus, with cost reduction plans and manufacturing capacity expansions underway. Risks include regulatory uncertainty, intense competition, reliance on market acceptance, and continued financial losses. Capital allocation policy is not disclosed; no dividends or buybacks are mentioned. The outlook is cautiously optimistic, grounded in platform breadth but tempered by execution and competitive headwinds.
Show extraction ▾Hide extraction ▴
MD&A highlights
·Total revenue of $1.9 billion in 2025, largely from sales of COVID vaccines.
·mNEXSPIKE launched commercially in Q3 2025; now leading product in U.S. retail channel.
·Phase 2b study of intismeran autogene (mRNA-4157) with Merck showed 49% reduction in recurrence risk at 5 years in high-risk melanoma.
·mRNA-1010 influenza vaccine BLA accepted by FDA with PDUFA date August 5, 2026; regulatory filings also in Europe, Canada, Australia.
·mRNA-1083 (flu+COVID combination) under regulatory review in Europe and Canada.
·mRNA-3927 for propionic acidemia reached target enrollment in registrational study; strategic collaboration with Recordati in January 2026.
·CEPI agreed to invest up to $54.3 million for Phase 3 trial of pandemic flu vaccine mRNA-1018.
·Marlborough facility for intismeran began clinical batch supply in September 2025.
·Manufacturing facilities in UK, Canada, Australia fully licensed in 2025 with multi-year government purchase commitments.
Guidance
Management expects revenue growth in 2026 from the annualized impact of long-term partnerships in the UK, Canada, and Australia, as well as continued strong uptake of mNEXSPIKE in the U.S. They anticipate further cost reductions in 2026 and 2027, leveraging global production network, AI, and digital tools. Multiple new product launches (flu, flu+COVID combination, norovirus) are expected over the next few years.
Backlog
Multi-year purchase commitments from the governments of the UK, Canada, and Australia for mRNA products from local manufacturing facilities, which were fully licensed in 2025.
Debt / leverage
Project financing from Blackstone Life Sciences supports the flu vaccine development; a secured term loan facility exists but details are not fully described in the excerpt.
Key risks
·Regulatory and market uncertainty impacting business and product markets.
·Difficulties executing near-term strategy and prioritized pipeline.
·Intense competition in vaccine and pharmaceutical markets.
·Commercial challenges and dependence on market acceptance and reimbursement.
·Lengthy and uncertain clinical development; potential delays or termination.
·Dependence on single-source suppliers for components and materials.
·Inability to obtain and enforce patent protection; intellectual property litigation.
·Net losses in 2025 and 2024, with expectation of additional losses; limited history of profitability.
·Cybersecurity risks and potential breaches of internal systems.
Forward-looking · richest in 10-Ks
Outlook / tone
Management expresses a cautiously optimistic outlook, stating 'We expect to drive revenue growth in 2026' and 'We believe that the development of mRNA medicines represents a significant breakthrough,' while acknowledging 'We incurred net losses in 2025 and 2024, and expect to incur additional losses in the future.' The tone is confident in the platform's potential but pragmatic about near-term financial challenges and competitive dynamics.
Strategic priorities
·Deliver sales growth through geographic expansion and new product launches.
·Deliver cost efficiency across the business via manufacturing, R&D, and SG&A improvements.
·Execute on our prioritized pipeline with pivotal data readouts and product launches.
·Continue to advance our early pipeline and platform technology across modalities.
Capex / expansion
Construction began in 2025 at the MTC campus for new commercial drug product manufacturing and packaging capability; Marlborough facility completed for intismeran clinical supply; international facilities in UK, Canada, Australia fully licensed in 2025.
Risk-factor changes
The summary of material risks emphasizes execution of near-term strategy and commercial challenges, reflecting the transition from pandemic-driven demand to an endemic and pipeline-dependent model. New risks include difficulties in executing the prioritized pipeline and commercial challenges in a competitive market.
Extracted by deepseek-v4-flash · Jul 23, 2026
8-KFeb 13, 2026Item 2.02,9.01unprocessed
Source ↗
Facts ingested; qualitative extraction pending.
8-KFeb 11, 2026Item 7.01,8.01,9.01routine
Source ↗
Routine 8-K — kept for the record, not extracted.
8-KJan 12, 2026Item 2.02,7.01,9.01unprocessed
Source ↗
Facts ingested; qualitative extraction pending.
8-KJan 05, 2026Item 7.01,9.01routine
Source ↗
Routine 8-K — kept for the record, not extracted.
8-KNov 24, 2025Item 1.01,2.03,9.01unprocessed
Source ↗
Facts ingested; qualitative extraction pending.
8-KNov 20, 2025Item 7.01,9.01routine
Source ↗
Routine 8-K — kept for the record, not extracted.
8-KNov 13, 2025Item 5.07routine
Source ↗
Routine 8-K — kept for the record, not extracted.
10-QNov 06, 2025
Source ↗
Moderna's Q3 2025 results reflect the ongoing transition from pandemic-driven demand to a seasonal respiratory vaccine market, with net product sales declining 47% year-over-year to $973 million and a net loss of $0.51 per share. Pipeline execution saw a major setback with the late-stage failure of its CMV vaccine, while positive data for the new COVID vaccine mNEXSPIKE and progress with the seasonal flu vaccine mRNA-1010 provide near-term catalysts. The company continues to build out international manufacturing capabilities, with facilities in Australia, UK, and Canada now operational. Despite the net loss, the balance sheet remains strong with $6.6 billion in cash and no long-term debt, supporting ongoing R&D investment.
Show extraction ▾Hide extraction ▴
MD&A highlights
·Net product sales for Q3 2025 were $973 million, down from $1.8 billion in Q3 2024.
·Net loss per share was $(0.51) for Q3 2025, compared to net income per share of $0.03 in Q3 2024.
·mNEXSPIKE, the new COVID vaccine, was approved by the FDA in May 2025 for adults aged 65+ and individuals 12-64 with at least one underlying risk factor, with commercial launch in Q3 2025.
·mRESVIA (RSV vaccine) was approved for adults 18-59 at increased risk for RSV disease in June 2025.
·mRNA manufacturing facilities in Australia and the UK became licensed and operational in Q3 2025; the first mRNA vaccines fully manufactured in Canada were delivered from the Laval, Quebec facility.
·Positive preliminary Phase 4 immunogenicity data for the 2025-2026 formulas of Spikevax and mNEXSPIKE were announced, with greater than 8-fold and 16-fold increases in neutralizing antibodies, respectively.
·Phase 3 efficacy and safety data for seasonal flu vaccine mRNA-1010 were presented at IDWeek 2025; submissions for approval expected by January 2026.
·Phase 3 trial for CMV vaccine mRNA-1647 did not meet its primary efficacy endpoint; the congenital CMV clinical development program will be discontinued.
·Norovirus vaccine Phase 3 study will enroll an additional Northern Hemisphere season due to insufficient case accruals.
Key risks
·Our ability to drive use of our commercial products and to increase market share.
·Our ability to execute on our prioritized research and development portfolio.
·Unforeseen challenges in the development of our product candidates, including clinical trial failures.
·Manufacturing and supply chain risks, including reliance on third-party suppliers.
·Intellectual property litigation, including patent infringement actions against Pfizer/BioNTech and from Arbutus, GSK, and Northwestern University.
·Seasonal fluctuations in demand for COVID and RSV vaccines.
·Competition in the COVID and RSV vaccine markets.
·Potential delays in regulatory approvals for pipeline candidates.
Forward-looking · richest in 10-Ks
Outlook / tone
The Company expects seasonal fluctuations in demand for its COVID and RSV vaccines, with higher sales anticipated during the fall and winter seasons. For the seasonal flu vaccine mRNA-1010, the company expects to complete submissions for approval in the U.S., Canada, Australia, and Europe by January 2026. The flu+COVID combination vaccine mRNA-1083 is under review with the EMA; the company expects to refile with Health Canada in 2025 and is awaiting further FDA guidance. The norovirus vaccine Phase 3 study will continue into a second Northern Hemisphere season. The CMV vaccine program has been discontinued following a Phase 3 efficacy miss. The company has adequate liquidity, with cash, cash equivalents, and investments totaling $6.6 billion as of September 30, 2025.
Strategic priorities
·Continue to drive use of commercial products (Spikevax, mNEXSPIKE, mRESVIA).
·Execute on a prioritized R&D portfolio across respiratory virus vaccines, latent and other virus vaccines, oncology, and rare disease.
·Deliver cost efficiency across the business.
·Expand international mRNA manufacturing capabilities through strategic agreements with governments.
·Advance pipeline candidates including seasonal flu vaccine mRNA-1010 and flu+COVID combination vaccine mRNA-1083.
Risk-factor changes
There have been no material changes from the risk factors described in the Company's 2024 Form 10‑K.
Extracted by deepseek-v4-flash · Jul 23, 2026
8-KNov 06, 2025Item 2.02,9.01unprocessed
Source ↗
Facts ingested; qualitative extraction pending.

Review queue · nothing auto-saves

News & signals

3 queued

neutrallow magnitudemedium-termtrade-presstoday
mRNA cancer vaccines’ biggest barriers to market
Auto-collected from BioPharma Dive; awaiting human review.
Source ↗
neutrallow magnitudemedium-termtrade-presstoday
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Auto-collected from BioPharma Dive; awaiting human review.
Source ↗
neutrallow magnitudemedium-termtrade-presstoday
Cancer vaccine win restores Wall Street’s faith in Moderna
Auto-collected from BioPharma Dive; awaiting human review.
Source ↗
neutrallow magnitudemedium-termtrade-presstoday
FDA approves Moderna’s mRNA flu vaccine
Auto-collected from Healthcare Dive; awaiting human review.
Source ↗
approved
neutrallow magnitudemedium-termtrade-presstoday
FDA approves Moderna’s mRNA flu vaccine
Auto-collected from BioPharma Dive; awaiting human review.
Source ↗
approved

Illustrative data where noted. Not investment advice.